कंपनी का अवलोकन
REGENXBIO Inc. is a clinical-stage biotechnology entity dedicated to delivering functional genes to cells possessing genetic defects throughout the United States. The organization utilizes its proprietary NAV Technology Platform, which functions as a specialized adeno-associated virus gene delivery system for its product candidates. This firm operates within the Healthcare sector, specifically targeting the Biotechnology industry, a domain characterized by high innovation costs and long development cycles. The company currently maintains a market capitalization of $400.52M and employs 371 individuals to support its operations. With a trailing twelve-month revenue of $170.44M, the firm demonstrates a significant operational scale for a clinical-stage entity, indicating substantial market engagement despite the lack of commercialized product revenue typical in early development phases.
वित्तीय स्वास्थ्य
The company reported a total revenue of $170.44M for the trailing twelve months, yet posted a net income of $-193,878,000 and an EBITDA of $-145,583,008. The substantial divergence between positive revenue and significant negative net income reveals a cost structure dominated by heavy research and development expenditures and operational overheads common in gene therapy development. Free cash flow stands at $-79,794,752, indicating that the company is burning through cash reserves to fund its proprietary technology pipeline and clinical trials. Gross margin is recorded at -45.9%, while operating margin is -190.0%, and profit margin is -113.8%, all of which reflect the intense cost pressures inherent in bringing novel therapies to market before achieving commercial scale. The balance sheet holds $230.07M in cash against $260.52M in debt, resulting in a debt-to-equity ratio of 253.59, which characterizes a highly leveraged financial position relative to its equity base. Despite the leverage, the current ratio of 2.38 suggests that the company maintains adequate short-term liquidity to cover its current liabilities with current assets. Return on Equity is -107.0% and Return on Assets is -21.9%, metrics that indicate management is currently deploying capital to generate losses rather than profits, a standard but risky phase for biotechnology firms seeking clinical validation.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings, while the Forward P/E is -3.53. The negative forward P/E implies that analysts or market models anticipate earnings will remain negative in the near term, or that the market is pricing in a long path to profitability. The price-to-book ratio is 3.84, suggesting that the market values the company at nearly four times its tangible book value, a premium often attributed to the potential intrinsic value of its intellectual property and NAV Technology Platform. Alternative valuation measures such as a price-to-sales ratio of 2.35 and an EV/EBITDA of -2.96 provide context for investors assessing the firm's value relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization. The stock's trading range over the past year spans from a low of $5.04 to a high of $16.19, meaning the current share price sits significantly below the 52-week high while remaining well above the 52-week low, reflecting high volatility. The beta of 1.14 indicates that the stock price is more volatile than the broader market, moving with greater intensity during periods of market fluctuation, which is typical for smaller-cap biotechnology stocks.
Growth & Income
Revenue growth year-over-year is 43.0%, demonstrating a robust expansion in sales or grant income, whereas earnings growth is N/A due to the company's persistent net losses. The absence of positive earnings growth relative to revenue highlights that top-line expansion is being consumed by rising costs rather than translating into immediate profitability, a pattern frequently observed in clinical-stage biotech. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the firm does not distribute income to shareholders, the company reinvests all available capital and proceeds from financing activities back into its research, development, and clinical trial programs to advance its gene therapy candidates. The overall growth and income profile indicates a pure-play growth strategy where investors accept current cash burn and lack of income distribution in exchange for potential future value realization upon successful product commercialization.